Tourmaline Bio's Pacibekitug shows promise in IL-6 targeting for autoimmune diseases. Learn about its potential and ongoing trials. Read why TRML is a hold.
Delaware courts issued multiple instructive decisions on earnout provisions in life sciences M&A transactions.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback